A naturally produced thymic peptide with one of the longest clinical research histories in immune modulation — approved as Zadaxin in over 35 countries.
Thymosin Alpha-1 is a peptide naturally produced by the thymus gland — the organ tucked behind your sternum that trains your immune system's T-cells. It's a 28-amino-acid chain that your body makes on its own, but researchers have been studying a synthetic version since the 1970s. It's one of the most clinically studied peptides in the immune support category, with human research data going back decades.
The thymus gland works like a training academy for immune cells. Immature T-cells arrive from the bone marrow and go through an intensive selection and training process. Thymosin Alpha-1 is one of the key peptides the thymus produces to facilitate this — essentially one of the academy's main teaching tools.
What makes Thymosin Alpha-1 particularly significant is that pharmaceutical versions (marketed as Zadaxin by SciClone Pharmaceuticals) have received regulatory approval in multiple countries for specific clinical indications, giving it a clinical research track record that most peptides in this library never achieve.
Among immune-focused peptides, Thymosin Alpha-1 stands out for the depth of its clinical research history — studied not just in laboratory settings but in human clinical trials spanning multiple decades and continents.
Thymosin Alpha-1 works by activating dendritic cells (the immune system's surveillance scouts) through Toll-like receptor interactions, triggering a cascade that amplifies their ability to present antigens to naive T-cells. It also stimulates T-helper cell maturation and shifts immune balance toward the Th1 profile — the branch of immunity responsible for fighting intracellular pathogens and cancer cells.
It influences natural killer (NK) cell activity and increases the production of cytokines like interferon-gamma and interleukin-2, which coordinate immune responses against viruses and abnormal cells.
Your immune system is an army. Raw recruits come in — they can fight, but they don't know what to target. The thymus gland is the military academy that teaches them to identify and engage specific enemies. Thymosin Alpha-1 is like adding more experienced drill sergeants to that academy — more recruits get trained faster, come out sharper, and are better at recognizing real threats in the field.
Investigación Renuncia de responsabilidad: Lo siguiente refleja investigación clínica y preclínica publicada y no es consejo médico. Consulta a un profesional de la salud licenciado antes de tomar decisiones de salud.
Thymosin Alpha-1 (Zadaxin/thymalfasin) is an approved drug in 35+ countries with a substantial published clinical trial record spanning hepatitis B/C, cancer immunotherapy, and COVID-19 research — providing extensive human dosing data.
Referencias Clave: Cheng AL et al. (1997). Thymosin alpha-1 hepatitis B. Hepatology. · Liu Y et al. (2020). Thymosin alpha-1 in COVID-19. J Infection. · Chen H et al. (2013). Thymosin alpha-1 in NSCLC. Oncol Rep.
Thymosin Alpha-1 is an approved pharmaceutical (Zadaxin) in over 35 countries, used for treating chronic hepatitis B and C and as adjunct cancer immunotherapy — one of the few peptides with this level of regulatory validation worldwide.
It was first isolated in the 1960s-70s by Dr. Allan Goldstein at Georgetown University, who spent decades studying thymus secretions before the broader scientific community recognized their clinical potential.
The thymus gland shrinks with age (thymic involution) — by age 65, most people have less than 15% of original thymic tissue remaining. This makes thymic peptides like Thymosin Alpha-1 particularly relevant to aging and immune resilience research.
Every batch of Thymosin Alpha-1 with full Certificate of Analysis documentation. Third-party HPLC verification, mass spectrometry confirmation, and sterility testing results are included with each batch.